GoodRx (NASDAQ:GDRX) Trading Down 5.4% on Analyst Downgrade

GoodRx Holdings, Inc. (NASDAQ:GDRX) fell 5.4% during trading on Monday after Citigroup lowered their price target on the stock from $11.00 to $10.00. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $6.73 and last traded at $6.82. 322,501 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 1,463,766 shares. The stock had previously closed at $7.21.

Several other research firms also recently weighed in on GDRX. Royal Bank of Canada raised shares of GoodRx from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $8.00 to $10.00 in a research note on Thursday, May 23rd. Morgan Stanley raised their target price on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th. Barclays upped their price target on GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Monday, May 20th. UBS Group reduced their price objective on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Finally, Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.36.

Institutional Investors Weigh In On GoodRx

A number of institutional investors have recently made changes to their positions in the stock. Raymond James & Associates purchased a new position in shares of GoodRx during the fourth quarter worth $192,000. International Assets Investment Management LLC purchased a new position in GoodRx during the 4th quarter valued at about $115,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in GoodRx by 82.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,006 shares of the company’s stock valued at $107,000 after acquiring an additional 7,244 shares in the last quarter. Syon Capital LLC purchased a new stake in GoodRx during the fourth quarter worth about $168,000. Finally, Victory Capital Management Inc. lifted its position in shares of GoodRx by 47.5% during the fourth quarter. Victory Capital Management Inc. now owns 31,760 shares of the company’s stock worth $213,000 after purchasing an additional 10,225 shares in the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Trading Up 1.3 %

The company has a debt-to-equity ratio of 1.02, a current ratio of 6.29 and a quick ratio of 6.29. The firm has a market cap of $2.58 billion, a PE ratio of -687.00, a price-to-earnings-growth ratio of 4.08 and a beta of 1.39. The company’s 50 day moving average price is $8.22 and its 200 day moving average price is $7.39.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $200.60 million for the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The firm’s revenue was up 5.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.02 EPS. As a group, analysts forecast that GoodRx Holdings, Inc. will post 0.17 EPS for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.